Research Insight

Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics. The drug was discovered and developed by Zydus Cadila, a pharmaceutical company based in India. Zydus...

Trophos and AFM-Telethon (The French Muscular Dystrophy Association) today announce that data from the pivotal clinical trial of Trophos’ lead product candidate olesoxime in spinal muscular atrophy (SMA) will be presented during the 66th American Academy of Neurology (AAN)...

Adocia (Euronext Paris: FR0011184241 - ADOC) announces positive results from a phase IIa clinical trial evaluating its innovative ultra-fast formulation of insulin Lispro in comparison to Eli Lilly’s Humalog(R) commercial insulin. Adocia’s formulation incorporates proprietary BioChaperone(R) technology which enables...

Immune cells undergo 'spontaneous' changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system, Melbourne scientists have found. The research team from the Walter and Eliza Hall Institute found...

Oramed Pharmaceuticals has released results of a Phase IIa clinical trial of its ORMD-0801, an oral insulin capsule for the treatment of type 2 diabetes. The trial was carried out under a US...

Immuneering Corporation announced today that it has entered into an agreement to expand its existing relationship with Bristol-Myers Squibb for the use of Immuneering’s proprietary computational biology methods to identify biological insights that may facilitate discovery...

The Innovative Medicines Initiative (IMI) is calling experts to join forces and tackle two challenges which are of major importance to public health. Measuring the combined benefits and risks of vaccines and assessing the effectiveness of...